Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 and Anlotinib in Advanced Lung Cancer
NCT07636226Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2026
- Primary completion
- Dec 2028
01
Overview
Phase 3, randomised, open-label trial of QL1706 in small cell lung cancer (SCLC) and squamous cell carcinoma of the lung (LSCC) (4 cohorts), sponsored by Sun Yat-sen University. Primary endpoint: Overall Survival at 36 months. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
small cell lung cancer (SCLC)squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT07636226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07636226.